VcR-Cap vs. R-CHOP

Phase III Study of the Combination of Rituximab, Cyclophos-phamide, Doxorubicin, VELCADE, and Prednison(VcR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Patients With Newly Diagnosed Mantle Cell Lymphoma who are not Eligible for a Bone Marrow Transplant.

Investigational product: VcR-CAP versus R-CHOP 

Indication: mantle cell lymphoma

Study design: randomised, open-Label, multicenter

Important criteria:

Inclusion: One or more measurable lesions,  no prior therapies for MCL, not eligible or not considered for bone marrow transplantation, ECOG status 0-2.
Exclusion: prior treatment with Velcade, specific laboratory ranges, major surgery within 2 weeks before randomization,  another primary malignancy within the last 1 year except completely resected basal cell carcinoma, squamous cell carcinoma of the skin or in situ malignancy, active systemic infection requiring treatment, serious medical or psychiatric illnes. 

Study physician at SanaFontis: PD. Dr. med. J. Drevs (PI)

Status: start 02/09

Further information:

Medical Information Service

Tel.:  +49 (0761) 888 59-58 74
Fax:  +49 (0761) 888 59-59 57

E-Mail: medinfo(at)sanafontis.com